Skip to content
skan cell atmp

Advanced Therapy Medicinal Products (ATMPs)

Enabling safe, closed, and scalable manufacturing of advanced therapies

Learn more

Cell and gene therapies require uncompromised aseptic control from the very first process step as, unlike conventional/most pharmaceuticals, ATMPs cannot be terminally sterilized. They also involve cryogenic storage, complex regulatory pathways, and sometimes patient-specific materials.

At the same time, regulatory expectations continue to evolve. The implementation of EU GMP Annex 1 and the specific requirements of Annex 2B demand robust contamination control strategies and clearly justified process designs. In parallel, the FDA is strengthening expectations around aseptic processing and contamination control for advanced therapies.

In ATMP production, every open intervention increases contamination risk. Closing these steps is not only a regulatory expectation but also a fundamental requirement for patient safety.

At a glance

Key challenges in ATMP manufacturing

  • Open manipulations during processing, transfer, or filling

    Ensuring Grade A conditions during all critical process steps

  • Tech transfer & upscaling strategies

    Scaling from early clinical phases to commercial production

  • Safe storage and delivery of sensitive products

    Container closure integrity at cryogenic temperatures

  • Small or individual batches

    The production of patient specific treatments requires flexibility and fast processes

Critical points for aseptic integrity

Typical ATMP manufacturing workflow

  • 1

    Upstream processing

    Cell expansion, viral vector production, and genetic modification often require manual interventions or transfers. These represent high risk moments for contamination if not properly contained.

  • 2

    Downstream processing

    Purification, concentration, and formulation may involve open handling or product transfers, requiring controlled environments and validated contamination control strategies.

  • 3

    Fill & finish

    Final dosing into primary containers is one of the most critical operations, as contamination risks are highest during this step. Maintaining product protection through a secure filling process is essential to preserving aseptic integrity.

  • 4

    Cryogenic storage

    For many ATMPs, products must subsequently be stored under cryogenic conditions to maintain viability and therapeutic effect. Container systems must therefore remain fully integral at ultra-low temperatures without compromising GMP compliance or sterility assurance.

Addressing the challenges

Safe environment for ATMP manufacturing

ATMP manufacturing cannot rely on conventional pharmaceutical approaches. Processes must be engineered around the biological nature of the product and the regulatory framework governing advanced therapies.

  • Closed aseptic processing

    Technologies that eliminate open handling steps enhance sterility assurance and reduce operator-dependent variability. Converting open manipulations into closed systems is a key enabler of safe ATMP production.

  • Grade A manufacturing environments

    Isolator-based solutions provide validated Grade A conditions for fill & finish as well as critical upstream and downstream interventions. This ensures high contamination control while maintaining operational efficiency.

Inside chamber of the Cellana XL1 system.
Addressing the challenges

Standardized and validated processes

  • Small batch fill & finish

    Small-batch fill & finish plays a key role in ATMP manufacturing. With limited product quantity and high product value, product losses must be kept to a minimum. Specialized filling processes help maximize yield while maintaining sterility and product integrity.

    → Learn more about small-scale filling

  • Aseptic fluid transfer

    Maintaining sterility throughout the liquid transfer process is essential for ATMP manufacturing. Aseptic fluid transfer solutions help protect the product from contamination risks while ensuring a secure and controlled product path between manufacturing steps.

    → Learn more about fluid transfer

Close-up of a stainless steel AT-Port™ connection with a white tube attached, showing "START" and "STOP" markings - by SKAN.
Addressing the challenges

Special requirements for ATMP manufacturing

  • Cryogenic-compatible container strategies

    Advanced therapies often require storage at ultra-low temperatures. Container systems must maintain integrity under cryogenic conditions, overcoming limitations associated with traditional bags or non-GMP screw-cap solutions.

    → Whitepaper: “Container Closure Integrity at Cryogenic Temperatures”

  • Regulatory expertise – Annex 1 & Annex 2B

    Advanced therapy manufacturing requires a clear contamination control strategy aligned with Annex 1, combined with ATMP-specific considerations under Annex 2B. Process design, validation concepts, and documentation must reflect both.

  • Designed for future scale

    ATMP manufacturing often starts with small-batch filling for development and clinical trials. However, early process and equipment choices should already account for future scale-up or scale-out requirements. Planning ahead helps ensure a smooth transition to commercial production without major process changes.

Closed vial system.

Expertise for ATMP manufacturing

The evolving ATMP landscape brings new therapeutic formats, manufacturing models, and regulatory challenges. Successful production requires more than equipment; it demands a deep understanding of aseptic processing, biological constraints, and regulatory expectations.

For over 20 years, SKAN has partnered with ATMP manufacturers, delivering more than 500 tailored solutions across autologous and allogeneic manufacturing models.

Through close collaboration and co-development, we support manufacturers at every stage of development, from transitioning manual open processes to closed Grade A systems and implementing cryogenic-stable container strategies to scaling production while maintaining process consistency and regulatory compliance.

By combining engineering expertise with industry knowledge, we help manufacturers design closed, compliant, and scalable processes that protect both product and patient.

Let’s talk about your ATMP project

Let’s discuss how to design a closed, compliant, and scalable ATMP manufacturing strategy tailored to your needs.

Our solutions for ATMP manufacturing

Back to top